Categorized | Stock Newsletters
*** SHMN’s Fundamental and Technical Factors Look Impressive ***
Posted on 27 August 2010 by admin
Sohm, Ink (OTCPK: SHMN) has a well diversified portfolio, which covers virtually all major treatment categories.
Within it's international market segment, SHMN has shown impressive growth that includes record revenue growth and outlook.
Fundamentally, that could justify an increase in share price.
SHMN also looks like it could make a move upwards from a technical standpoint...
-------------------------------------
For those interested in SHMN's marketing program aimed at expanding its market share internationally, below are two countries the Company has pursued which have indicated robust growth potential:
(1) India
The company’s management expressed its hope that the company will benefit from its manufacturing base in India. The company’s Vice President for Corporate Strategy, Shailesh Shah said, “SOHM's strategy and commitment to offer medicine to all people in India where many are under the poverty line has rewarded us with a loyal customer base and we will continue to build the SOHM brand throughout India.”
(2) Philippines
The company has also received $750,000 worth of purchase order for pharma distribution in Philippines. The Philippine drug market is expected to be worth $4 billion by 2012.
The company has also received $750,000 worth of purchase order for pharma distribution in Philippines. The Philippine drug market is expected to be worth $4 billion by 2012.
(3) Africa
SHMN announonced that has signed a sales and marketing agreement to sell its branded generic pharmaceutical products in Africa. Sales will begin in Uganda, Tanzania, and Zambia under the SOHM brand as soon as the necessary measures have been completed in each country. All of the generic drugs will be produced by SOHM’s India-based licensed manufacturing facility.
Stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. “We made a strong commitment to globalize our branded generic pharmaceutical product line and we are well on our way with our new partner in Africa. We have rapidly expanded our market share in India and feel confident we will be very successful in Africa as well. Africa’s challenges, like high cases of disease and booming populations, are solid market opportunities..."
----------------------------------------------------
SHMN looks like it has the factors to be an undiscovered gem based upon both fundamental and technical standpoints.
They also have announced:
(1) an expansion of their manufacturing facility as well as their pharmaceutical line to 280 products
(3) announced intent to transition to OTCBB Quotation System, per their May 5th announcement.
---------------------------------------------
SHMN looks like Company worth considering.
Watch for demand for shares to increase which I expect to could have a parallel increase in price-per-share.
Best Regards,
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. ****************************************************************************************************************** The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: The PennyStockPickAlert employees are not Registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://www.pennystockpickalert.com/disclaimer Release of Liability: Through use of this website viewing or using you agree to hold PennyStockPickAlert, its operators owners and employees harmless and to compltely release them from any and all liability due to any and all loss (monetary or otherwise), damage
(monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. PennyStockPickAlert's affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. PennyStockPickAlert encourages readers and investors to supplement the information in these reports with independent research and other pro advice. PennyStockPickAlert has agreed to be compensated fifty thousand dollars for a one week investor awareness campaign by B&W, LLC. All information on featured companies is provided by the companies profiled, or is available from public sources and PennyStockPickAlert makes no representations, warranties or guarantees as to
the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to or sell any securities. Any claims or Statements should be deemed apocryphal. PennyStockPickAlert, nor any of its affiliates are not registered investment advisors or a broker dealers.
|
|
0 Comments For This Post
1 Trackbacks For This Post
-
TREVOR Says:
September 12th, 2010 at 4:46 pmBuy:Buspar.Zetia.Ventolin.Cozaar.Zocor.Wellbutrin SR.Seroquel.Acomplia.Amoxicillin.Female Pink Viagra.Female Cialis.Advair.Nymphomax.Lipothin.SleepWell.Lipitor.Lasix.Aricept.Prozac.Benicar….
Leave a Reply
You must be logged in to post a comment.